Estrogen Injections therapy, a clear guide.

Patients sometimes ask about injectable oestrogen, particularly estradiol valerate or estradiol cypionate, which are routinely used in the United States and some European countries. The active ingredients are clinically well-established; the issue isn't safety per se, but the UK licensing and prescribing landscape, which doesn't currently include injectable oestradiol for gender-affirming care.

What we use instead achieves the same end-point: serum oestradiol in the 400-800 pmol/L target range with testosterone suppressed below 3 nmol/L. Sandrena gel (transdermal) is our default first-line: a steady daily dose that avoids first-pass liver metabolism and carries a significantly lower VTE risk than oral routes. For patients who prefer a less daily regimen, Evorel patches deliver oestradiol over 3-4 days. Oral or sublingual oestradiol (Zumenon, Progynova, Estradiol Valerate) is available where transdermal absorption is sub-optimal, though it carries a slightly higher VTE risk.

For the vast majority of feminising patients, our standard transdermal and oral routes achieve excellent serum levels and clinical effect. Patients researching injectable protocols online sometimes feel the UK position is more conservative than it needs to be. That's a fair perspective, but as a UK-regulated clinic we work within UK licensing.